Company Overview - Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals for large patient populations, including those not addressed by existing technologies [5] - The company's most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with potential applications across multiple tumor types [5] - Aktis has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver tumor-killing properties of radioisotopes to targeted tumors while minimizing side effects [5] - The platform is isotope-agnostic and allows clinicians to visualize and verify target engagement with imaging isotopes before therapeutic exposure [5] - Aktis has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates outside of its proprietary pipeline [5] IPO Details - Aktis announced the pricing of its upsized initial public offering of 17,650,000 shares at a price of $18.00 per share, with gross proceeds expected to be approximately $318.0 million [1] - The underwriters have a 30-day option to purchase up to an additional 2,647,500 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026, with the offering expected to close on January 12, 2026 [1]
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering